The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.

Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

The Broad Institute gene-sequencing lab used Roche equipment to read infants’ DNA genomes in less than four hours, cutting an ...

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing ...

Unlike conventional methylation conversion technologies, Illumina's proprietary conversion chemistry selectively converts methylated cytosine to thymine. This selective conversion of methylated ...

Illumina launches BioInsight, a new business to accelerate technology and data-driven discovery: San Diego Saturday, October 4, 2025, 14:00 Hrs [IST] Illumina, Inc., a global geno ...

Illumina (ILMN) just launched BioInsight, a new business unit focused on combining sequencing, software, and AI for advanced biological insights. Executive changes and this expansion highlight the ...

Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx .

US-based company is developing next-generation sequencers, using AI models in the Republic to speed up diagnostics and lower ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...